Tag: DAPA-HF

New data from the Phase III DAPA-HF trial showed FARXIGA reduced the worsening of heart failure or cardiovascular death in HFrEF patients with and without chronic kidney disease

Coronary/Structural Heart by 0 comments

AstraZeneca today announced a pre-specified sub-analysis from the landmark Phase III DAPA-HF trial investigating FARXIGA® (dapagliflozin) for the treatment of heart failure (HF). The data showed that FARXIGA on top of standard of care reduced the incidence of the primary […]

Continue Reading →